ReviewNature chemistry2016
Counting on natural products for drug design.
Review in Nature chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 382 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
382 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review on Natural Products, Nanotechnology and their Recent Updates Towards Management of CFA-induced Rheumatoid Arthritis.Current drug discovery technologies · 2026Pooled it
- Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2023Pooled it
- Unveiling the anticancer potential of genus Aerva as therapeutics for CLL (Chronic Lymphocytic Leukemia): from plant to patient.Folia microbiologica · 2026Article
- Design, synthesis, and quantitative structure-antifungal activity relationship of 1,2,4-oxadiazole-containing mappicine derivatives against phytopathogenic fungi.Pest management science · 2026Article
- Single-Cell Transcriptomic Integration Identifies LTA4H as an Immune-Associated Therapeutic Target in Hepatocellular Carcinoma.Cell biochemistry and biophysics · 2026Article
- A computational framework for proteome-wide target profiling of natural products: mechanistic and therapeutic insights into ginsenosides.Briefings in bioinformatics · 2026Article
- Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer.EMBO molecular medicine · 2026Article
- Marine-Derived Natural Products Against Flaviviruses: Mechanisms, Evidence, and Future Directions.Marine drugs · 2026Review
- SuFEx-Enabled Reprogramming of Flavonoids for Selective α-Glucosidase Covalent Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Plant-Based Therapeutics Against Communicable Diseases: A Review of Ethnopharmacology and Medicinal Chemistry Approaches.Chemistry & biodiversity · 2026Review
- Molecular imaging-guided discovery of a potent natural FAPα inhibitor for liver fibrosis therapy.Nature communications · 2026Article
- Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Discovery of natural RORγt inhibitor using machine learning, virtual screening, and in vivo validation.Journal of advanced research · 2026Article
- Repositioning Natural Products in Modern Drug Discovery: Technological Innovation, Systems Pharmacology, and Pathological Validation.International journal of molecular sciences · 2026Review
- Natural Products Beyond Inhibition: A Mechanistic Framework Spanning Pockets, Interfaces, and Kinetic Barriers.Molecules (Basel, Switzerland) · 2026Review
- Article
- Artificial intelligence-based screening of phytochemicals for targeted cancer therapy.Natural products and bioprospecting · 2026Review
- Article
- Evidence of Antiproliferative Activity in the LiverwortMolecules (Basel, Switzerland) · 2026Article
322 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products and their molecular frameworks have a long tradition as valuable starting points for medicinal chemistry and drug discovery. Recently, there has been a revitalization of interest in the inclusion of these chemotypes in compound collections for screening and achieving selective target modulation. Here we discuss natural-product-inspired drug discovery with a focus on recent advances in the design of synthetically tractable small molecules that mimic nature's chemistry. We highlight the potential of innovative computational tools in processing structurally complex natural products to predict their macromolecular targets and attempt to forecast the role that natural-product-derived fragments and fragment-like natural products will play in next-generation drug discovery.
Indexed as
Identifiers
27219696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.